Quarterly report [Sections 13 or 15(d)]

Stockholders’ Equity (Deficit)

v3.26.3
Stockholders’ Equity (Deficit)
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Stockholders’ Equity (Deficit)

Note 3 – Stockholders’ Equity (Deficit)

 

The Company’s authorized capital as of September 30, 2026 was 25,000,000 shares of Common Stock, par value $0.001 per share, and 1,500,000 shares of preferred stock, par value $0.01 per share (see Note 7 – Subsequent Events).

 

2025 Private Placement of Equity Facility (the “Committed Equity Facility”)

 

On May 14, 2025, and as amended on June 10, 2025, the Company entered into a common shares purchase agreement (the “Common Shares Purchase Agreement”) with investors (collectively, the “Investors”) relating to the Committed Equity Facility. Pursuant to the Common Shares Purchase Agreement, the Company has the right from time to time at its option to sell to the Investors up to $20 million of its Common Stock subject to certain conditions and limitations set forth in the Common Shares Purchase Agreement.

 

Sales of the shares of Common Stock to the Investors under the Common Shares Purchase Agreement, and the timing of any sales, will be determined by the Company from time to time in its sole discretion and will depend on a variety of factors, including, among other things, market conditions, the trading price of the Common Stock and determinations by the Company regarding the use of proceeds from the sale of such shares of Common Stock. The net proceeds from any sales under the Common Shares Purchase Agreement will depend on the frequency with, and prices at, which the shares of Common Stock are sold to the Investors.

 

The purchase price of the shares of Common Stock that the Company elects to sell to the Investors pursuant to the Common Shares Purchase Agreement will be 93% of the volume weighted average price of the shares of Common Stock during the applicable purchase date on which the Company has timely delivered written notice to the Investors directing them to purchase shares of Common Stock under the Common Shares Purchase Agreement.

 

In connection with the execution of the Common Shares Purchase Agreement, the Company agreed to issue to the Investors pre-funded warrants to purchase an aggregate of 12,000 shares of Common Stock as consideration for their irrevocable commitment to purchase the shares of Common Stock upon the terms and subject to the satisfaction of the conditions set forth in the Common Shares Purchase Agreement.

 

2025 Warrant Inducement Transaction

 

On February 26, 2025, the Company received gross proceeds of $686,000 before deducting placement agent fees and other offering expenses of $70,000 in relation to a warrant exercise inducement agreement with certain holders of existing warrants. The existing warrants were exercisable into 12,082 shares of Common Stock at $108.75 per share. The holders agreed to exercise these existing warrants at a reduced exercise price of $56.75 per share in exchange for the Company’s agreement to issue the holders new warrants (the “Inducement Warrants”) exercisable for an aggregate of up to 24,165 shares of Common Stock.

 

The Inducement Warrants consist of (i) new Series A Inducement Warrants, representing warrants to purchase up to 12,082 shares of Common Stock at $50.50 per share exercisable immediately upon issuance with a term of five years from the date of issuance, and (ii) new Series B Inducement Warrants, representing warrants to purchase up to 12,082 shares of Common Stock at $50.50 per share exercisable immediately upon issuance with a term of eighteen months from the date of issuance. In addition, the Company issued warrants to the placement agent to purchase 846 shares of Common Stock at $70.94 per share exercisable immediately upon issuance with a term of five years from the date of issuance.

 

 

The Company determined that under ASC 815, the 2025 inducement and placement agent warrants are considered indexed to the Company’s own stock and eligible for an exception from derivative accounting. Accordingly, the fair value of the 2025 inducement and placement agent warrants is classified as equity.

 

The Company recognized the aggregate effect of the modification of warrants and grant of inducement warrants of $1.1 million as an equity issuance cost and the accounting effect is recognized in the Statement of Stockholders’ Equity (Deficit).

 

Preferred Stock

 

On September 2, 2026, the Company filed Certificates of Elimination (collectively, the “Certificates of Elimination”) to the Restated Certificate of Incorporation of the Company (the “Charter”) with the Secretary of State of the State of Delaware. The Certificates of Elimination eliminated from the Charter all matters set forth in the applicable Certificates of Designations with respect to the following series of preferred stock: (i) the Series A Preferred Stock; (ii) the Series B Preferred Stock; (iii) the Series C Preferred Stock; (iv) the Series D Preferred Stock; (v) the Series E Preferred Stock; (vi) the Series F Preferred Stock; (vii) the Series G Preferred Stock; (viii) the Series H Preferred Stock; (ix) the Series I Preferred Stock; (x) the Series J-1 Preferred Stock; and (xi) the Series K Preferred Stock (collectively, the “Eliminated Preferred Stock”).

 

Series C Preferred Stock

 

Prior to filing the Certificate of Elimination regarding the Series C Preferred Stock all 96,230 outstanding shares of Series C Preferred Stock were converted in accordance with their terms on September 2, 2026. As a result of numerous reverse stock-splits in previous years and the agreement terms for adjusting the rights of the related shares, such shares of Series C Preferred Stock were converted into an infinitesimal amount of Common Stock. As of September 30, 2026, there were no shares of Series C Preferred Stock issued and outstanding. No dividends to holders of the Series C Preferred Stock were declared or unpaid through September 30, 2026.

 

Series L Preferred Stock and Warrants

 

The Company previously issued shares of Series L Preferred Stock and related warrants (the “2025 Warrants”) pursuant to a securities purchase agreement entered into in May 2025, as more fully described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

 

As of September 30, 2025, there were 413 shares of Series L 10% Convertible Preferred Stock, par value $0.01 per share (the “Series L Preferred Stock”), issued and outstanding that were convertible into 36,347 shares of Common Stock using a conversion price of $11.35 per share (the conversion price in effect as of September 30, 2025).

 

Series L Preferred Stock and Warrant Activity During the Nine Months Ended September 30, 2026

 

During the nine months ended September 30, 2026, holders exercised certain additional purchase rights issued pursuant to the May 2025 private placement (the “Series L Greenshoe Rights”) and purchased 4,952 shares of Series L Preferred Stock with an aggregate stated value of $4,952,000 for total gross proceeds of $4,456,500. As a result of these issuances and the full-ratchet anti-dilution provisions, the conversion price of the Series L Preferred Stock was reduced to the contractual floor price of $11.35 per share on February 10, 2026, and remained at $11.35 as of September 30, 2026.

 

The reduction in the conversion price constituted a dilutive issuance under the terms of the 2025 Warrants. Accordingly, the exercise price of the outstanding 2025 Warrants was reduced, and the number of shares underlying the 2025 Warrants was increased, such that the aggregate exercise price of the 2025 Warrants remained unchanged.

 

For the nine months ended September 30, 2026, the incremental change in the fair value of equity classified instruments upon the reduction of conversion and exercise prices was determined to be $433,000, and was treated as a deemed dividend.

 

Series M Preferred Stock and Warrants

 

As of September 30, 2026, there were 7,171 shares of Series M Preferred Stock, issued and outstanding that were convertible into 1,175,657 shares of Common Stock using a conversion price of $6.10 per share (the conversion price in effect as of September 30, 2026).

 

On September 14, 2026, the Company entered into a securities purchase agreement (as amended on September 18, 2026, the “September 2026 Securities Purchase Agreement”) with certain purchasers (the “Purchasers”) providing for the issuance and sale of (i) 8,611.11 shares of Series M Preferred Stock with an aggregate stated value of $8,611,111; (ii) warrants to purchase up to 1,411,651 shares of Common Stock (the “Series M Common Warrants”) with an initial exercise price of $6.10 per share, exercisable immediately subject to certain ownership limitations, with a term of five years; and (iii) warrants to purchase 5,684,522 shares of Common Stock that vest upon exercise of the Series M Greenshoe Rights as defined below with an initial exercise price of $6.10 per share, exercisable immediately subject to certain vesting and ownership limitations, with a term of five years from the date that the applicable warrant shares vest (the “Series M Vesting Warrants,” and together with the Series M Common Warrants, the “2026 Warrants”). The aggregate purchase price of the Series M Preferred Stock and the 2026 Warrants was $7,750,000, and net proceeds were $7,640,000.

 

 

Pursuant to the September 2026 Securities Purchase Agreement, each Purchaser may elect to purchase up to 34,676 additional shares of Series M Preferred Stock with an aggregate stated value of up to $34,675,615 (the “Series M Greenshoe Rights”) for an aggregate purchase price of $31,208,054, subject to adjustments. Each Purchaser is entitled to exercise its respective Series M Greenshoe Rights in the ratio of such Purchaser’s original subscription amount to the original aggregate subscription amounts of all Purchasers.

 

On September 14, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series M 10% Convertible Preferred Stock (the “Series M Certificate of Designation”) with the Secretary of State of the State of Delaware.

 

The shares of Series M Preferred Stock and 2026 Warrants both have full-ratchet price and anti-dilution protections and are subject to other adjustments, as further described in the Series M Certificate of Designation or the 2026 Warrants, as applicable, subject, solely with respect to adjustments in connection with the exercise of Series M Greenshoe Rights. There will not be a floor price; provided, however, if the Company receives written notice from Nasdaq that a floor price should be implemented, a floor price of $1.282 per share shall be set (the “Series M Floor Price”), subject to adjustment for reverse and forward splits, recapitalizations and similar transactions.

 

In connection with our entry into the September 2026 Securities Purchase Agreement, on September 14, 2026, we entered into a registration rights agreement with the Purchasers, pursuant to which we agreed to file a resale registration statement with respect to the public resale of the shares of Common Stock issuable upon conversion of the shares of Series M Preferred Stock and upon exercise of the 2026 Warrants not later than 30 calendar days after September 14, 2026 and after each closing of the exercise of a Series M Greenshoe Right in accordance with the September 2026 Securities Purchase Agreement, to become effective no later than 60 days after September 14, 2026 or each Trigger Date (as defined in the registration rights agreement), or in the event of a “full review” by the SEC, 90 days after September 14, 2026 or each Trigger Date. If these deadlines are not met, the Company will be liable for liquidated damages of 1.5% of the subscription amount paid by each Purchaser. Further, if the Company fails to pay such liquidated damages within 7 days from the date payable, the Company will pay interest thereon at the prime rate plus 12% to each holder of the registrable securities. The Company filed the registration statement on Form S-1 with the Securities and Exchange Commission on October 9, 2026, which was declared effective on October 20, 2026.

 

Pursuant to the September 2026 Securities Purchase Agreement, the Company agreed to hold a meeting of its stockholders at the earliest practical date after the execution of the Securities Purchase Agreement for the purpose of obtaining stockholder approval for the issuance, in the aggregate, of more than 19.99% of the number of shares of Common Stock outstanding on the date of the initial closing (“Stockholder Approval”). Stockholder approval was obtained pursuant to a special meeting of stockholders held on November 11, 2026.

 

The Company evaluated the Series M Preferred Stock, the Series M Greenshoe Rights and the 2026 Warrants under ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging. The Series M Preferred Stock is not mandatorily redeemable and is not redeemable at the option of the holder or upon events outside the Company’s control. Accordingly, the Series M Preferred Stock is classified in permanent equity, and the Series M Greenshoe Rights are not liabilities under ASC 480. The Series M Greenshoe Rights and the 2026 Warrants are indexed to the Company’s own stock and meet the conditions for equity classification under ASC 815-40. Their down round features do not affect that conclusion. The net proceeds of $7,640,000 were recorded in stockholders’ equity.

 

Series M Preferred Stock and Warrant Activity During the Nine Months Ended September 30, 2026

 

During the nine months ended September 30, 2026, the holders of the Company’s Series M Preferred Stock have converted approximately 1,440 shares of Series M Preferred Stock into 236,000 shares of Common Stock. The conversion price of the Series M Preferred Stock was $6.10 per share as of September 30, 2026.

 

Dividends

 

During the nine months ended September 30, 2026, the Company declared and paid dividends of approximately $190,000 to holders of Series L Preferred Stock, which were settled through the issuance of 19,680 shares of Common Stock.

 

During the nine months ended September 30, 2026, the Company declared and paid dividends in cash of approximately $39,000 to holders of Series M Preferred Stock.